Zdrowie i gospodarka · 23/04/2018
FDA Announces Draft Guidance for Developing Depot Buprenorphine Products for Opioid Dependence Treatment
The FDA has released a draft guidance document outlining the agency's expectations for developing and testing depot buprenorphine products for the treatment of opioid dependence.